Overview

* LENZ Therapeutics ( LENZ ) Q3 net loss was $16.7 mln, driven by increased SG&A expenses

* VIZZ received FDA approval and launched commercially in October 2025

* Over 5,000 VIZZ prescriptions filled by October 2025

Outlook

* Company to launch VIZZ direct-to-consumer campaign in Q1 2026

* LENZ anticipates broad VIZZ availability by mid-Q4 2025

* Company did not provide specific financial guidance

Result Drivers

* ECP ENGAGEMENT - Over 2,500 unique ECPs prescribed VIZZ, with more than 5,000 prescriptions filled by October 2025

* MARKETING STRATEGY - Partnership with Sarah Jessica Parker for a direct-to-consumer campaign launching in Q1 2026

* INTERNATIONAL EXPANSION - Licensing agreement with Laboratoires Théa for VIZZ commercialization in Canada

* SG&A EXPENSES - Increased to $27.6 million and $51.5 million for the three and nine months ended September 30, 2025, respectively, compared to $6.5 million and $19.5 million during the same periods in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$16.70

Income mln

Q3 -$18.88

Income mln

from

Operatio

ns

Q3 $31.38

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for LENZ Therapeutics Inc ( LENZ ) is $53.00, about 47.1% above its November 4 closing price of $28.05

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)